{"title":"Boosters for all is critical, not a luxury, Fauci says as FDA decision nears","link":"https://arstechnica.com/?p=1813932","date":1637187848000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2021/11/GettyImages-1351282176-800x533.jpeg\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2021/11/GettyImages-1351282176.jpeg\">Enlarge</a> (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/national-institute-of-allergy-and-infectious-diseases-news-photo/1351282176?adppopup=true\">Getty |  Chip Somodevilla</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>The Food and Drug Administration is expected to authorize booster doses of the Pfizer-BioNTech COVID-19 vaccine for all adults as early as Thursday, agency insiders told <a href=\"https://www.nytimes.com/2021/11/16/us/politics/fda-pfizer-booster-shot.html?action=click&amp;module=RelatedLinks&amp;pgtype=Article\">The New York Times</a> Tuesday.</p>\n<p>The reported timeline is remarkably fast-paced for the regulatory agency and comes as members of the Biden administration continue to suggest widespread boosting is necessary to bring the COVID-19 pandemic under control.</p>\n<p>\"I believe... that when we look back on this, we will see that boosters are likely a very critical part of the immunization regimen and not a bonus or a luxury,\" top infectious disease expert Anthony Fauci told Reuters on Tuesday.</p></div><p><a href=\"https://arstechnica.com/?p=1813932#p3\">Read 11 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1813932&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"3bfe3bef05c8fb9512dd260c4028df41f4d9b7e74d3ca34e79b45ac17acd4fa3","category":"Tech"}